Allen Capital Group’s Biogen BIIB Stock Holding History

Allen Capital Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,803	Closed	-$504K	–	158
2021 Q1	$504K	Buy	1,803 +395	+28%	+$107K	0.11%	98
2020 Q4	$345K	Buy	+1,408	New	+$363K	0.08%	114

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Allen Capital Group's BIIB Position: Q2 2021 in Review

Allen Capital Group sold out of Biogen (BIIB) in Q2 2021, closing a stake of 1,803 shares — an estimated $504K sold.

Allen Capital Group first reported a position in BIIB in Q4 2020 and held it in 2 quarters. The position peaked at $504K in Q1 2021. 1,104 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Allen Capital Group reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Allen Capital Group sold 1,803 Biogen shares in Q2 2021, an estimated $504K.
Allen Capital Group first reported a position in Biogen in Q4 2020 and held it in 2 quarters.
Allen Capital Group's Biogen position peaked at $504K in Q1 2021.
1,104 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Allen Capital Group's 13F filing for Q2 2021, filed 20 Jul 2021.